NCT00549185View on ClinicalTrials.gov

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
LymphomaNon-Hodgkin
Interventions
DRUG

SAR3419

Intravenous infusion

Trial Locations (1)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY